Format
Sort by
Items per page

Send to

Choose Destination

Best matches for oncolytic newcastle disease virus:

Search results

Items: 1 to 20 of 223

1.

Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.

Bai Y, Chen Y, Hong X, Liu X, Su X, Li S, Dong X, Zhao G, Li Y.

Sci Rep. 2018 Jul 31;8(1):11470. doi: 10.1038/s41598-018-29929-y.

2.

Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.

Jiang K, Song C, Kong L, Hu L, Lin G, Ye T, Yao G, Wang Y, Chen H, Cheng W, Barr MP, Liu Q, Zhang G, Ding C, Meng S.

BMC Cancer. 2018 Jul 18;18(1):746. doi: 10.1186/s12885-018-4522-3.

3.

[Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies].

Matveeva OV, Kochneva GV, Zainutdinov SS, Ilyinskaya GV, Chumakov PM.

Mol Biol (Mosk). 2018 May-Jun;52(3):360-379. doi: 10.7868/S0026898418030023. Russian.

4.

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.

Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D.

Oncotarget. 2018 Jun 19;9(47):28702-28716. doi: 10.18632/oncotarget.25614. eCollection 2018 Jun 19.

5.

Newcastle Disease Virus (PDQ®): Health Professional Version.

PDQ Integrative, Alternative, and Complementary Therapies Editorial Board.

PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.
2018 Jun 19.

6.
7.

Newcastle disease virus induces G0/G1 cell cycle arrest in asynchronously growing cells.

Wang Y, Wang R, Li Y, Sun Y, Song C, Zhan Y, Tan L, Liao Y, Meng C, Qiu X, Ding C.

Virology. 2018 Jul;520:67-74. doi: 10.1016/j.virol.2018.05.005. Epub 2018 May 26.

PMID:
29793075
8.

Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway.

Fan X, Lu H, Cui Y, Hou X, Huang C, Liu G.

Exp Ther Med. 2018 May;15(5):4522-4530. doi: 10.3892/etm.2018.5935. Epub 2018 Mar 8.

9.

Newcastle disease virus strain AF2240 as an oncolytic virus: A review.

Kalyanasundram J, Hamid A, Yusoff K, Chia SL.

Acta Trop. 2018 Jul;183:126-133. doi: 10.1016/j.actatropica.2018.04.007. Epub 2018 Apr 4. Review.

10.

Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.

Yurchenko KS, Zhou P, Kovner AV, Zavjalov EL, Shestopalova LV, Shestopalov AM.

PLoS One. 2018 Apr 5;13(4):e0195425. doi: 10.1371/journal.pone.0195425. eCollection 2018.

11.

Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.

Santry LA, McAusland TM, Susta L, Wood GA, Major PP, Petrik JJ, Bridle BW, Wootton SK.

Mol Ther Methods Clin Dev. 2017 Oct 16;9:181-191. doi: 10.1016/j.omtm.2017.10.004. eCollection 2018 Jun 15.

12.

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD.

J Clin Invest. 2018 Apr 2;128(4):1413-1428. doi: 10.1172/JCI98047. Epub 2018 Mar 5.

13.

Unleashing the therapeutic potential of oncolytic viruses.

Bommareddy PK, Kaufman HL.

J Clin Invest. 2018 Apr 2;128(4):1258-1260. doi: 10.1172/JCI120303. Epub 2018 Mar 5.

14.

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.

Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D.

Mol Ther. 2018 Apr 4;26(4):1008-1019. doi: 10.1016/j.ymthe.2018.01.019. Epub 2018 Jan 31.

15.

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

Lundstrom K.

Biologics. 2018 Feb 9;12:43-60. doi: 10.2147/BTT.S140114. eCollection 2018. Review.

16.

Antitumor effect of the Newcastle disease viral hemagglutinin-neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells.

Chen S, Zhang Q, Xu D, Li Y, Fan Y, Li W, Yin X, Zhang Y, Liu J, Li X, Sun L, Jin N.

Anticancer Drugs. 2018 Mar;29(3):197-207. doi: 10.1097/CAD.0000000000000575.

PMID:
29438228
17.

Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Ortega-Rivera OA, Quintanar JL, Del Toro-Arreola S, Alpuche-Solis ÁG, Esparza-Araiza MJ, Salinas E.

Oncol Lett. 2018 Jan;15(1):1246-1254. doi: 10.3892/ol.2017.7387. Epub 2017 Nov 9.

18.

Biochemical Variations in Cytolytic Activity of Ortho- and Paramyxoviruses in Human Lung Tumor Cell Culture.

Zhirnov OP.

Biochemistry (Mosc). 2017 Sep;82(9):1048-1054. doi: 10.1134/S0006297917090085.

19.

In vitro infectivity of oncolytic Newcastle Disease Virus: Correlation between plaque and fluorescent focus assays.

Rush BS, Coughlin ML, Sanyal G.

J Virol Methods. 2018 Jan;251:69-74. doi: 10.1016/j.jviromet.2017.09.029. Epub 2017 Oct 2.

PMID:
28982603
20.

Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells.

Raghunath S, Pudupakam RS, Allen A, Biswas M, Sriranganathan N.

J Biotechnol. 2017 Oct 20;260:91-97. doi: 10.1016/j.jbiotec.2017.09.015. Epub 2017 Sep 19.

PMID:
28935568

Supplemental Content

Loading ...
Support Center